ストックスクリーナーアプリを入手
5.43
3.21%
-0.18
アフターアワーズ：
5.39
-0.04
-0.74%
前日終値:
$5.61
開ける：
$5.5
24時間の取引高:
3.96M
Relative Volume:
1.58
時価総額：
$440.43M
収益：
$409.00K
当期純損益:
$-101.35M
株価収益率:
-3.311
EPS:
-1.64
ネットキャッシュフロー:
$-71.49M
1週間 パフォーマンス:
-4.90%
1か月 パフォーマンス:
+6.47%
6か月 パフォーマンス:
-36.64%
1年 パフォーマンス:
-22.65%
1日の値動き範囲:
$5.35
$5.585
1週間の範囲:
$5.35
$5.805
52週間の値動き範囲:
$3.553
$11.16
Altimmune Inc Stock (ALT) Company Profile
ALT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALT
Altimmune Inc
|
5.43 | 463.12M | 409.00K | -101.35M | -71.49M | -1.64 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Altimmune Inc Stock (ALT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-28 | 開始されました | William Blair | Mkt Perform |
| 2025-01-08 | 開始されました | Stifel | Buy |
| 2024-11-12 | 開始されました | UBS | Buy |
| 2024-04-29 | ダウングレード | Guggenheim | Buy → Neutral |
| 2024-01-24 | 開始されました | Goldman | Neutral |
| 2023-03-22 | ダウングレード | Goldman | Buy → Neutral |
| 2022-12-01 | 開始されました | Goldman | Buy |
| 2021-12-29 | 再開されました | Jefferies | Buy |
| 2021-06-02 | 開始されました | H.C. Wainwright | Buy |
| 2021-02-11 | 開始されました | Guggenheim | Buy |
| 2020-12-14 | 開始されました | Jefferies | Buy |
| 2020-11-12 | 繰り返されました | B. Riley Securities | Buy |
| 2020-09-25 | 開始されました | B. Riley FBR | Buy |
| 2020-08-14 | 開始されました | Evercore ISI | Outperform |
| 2020-07-31 | 開始されました | Piper Sandler | Overweight |
| 2020-07-28 | 開始されました | JMP Securities | Mkt Outperform |
| 2020-02-24 | 再開されました | ROTH Capital | Buy |
| 2019-07-19 | 開始されました | ROTH Capital | Buy |
| 2017-10-09 | 開始されました | Piper Jaffray | Overweight |
すべてを表示
Altimmune Inc (ALT) 最新ニュース
Investors who lost money on Altimmune, Inc.(ALT) should contact Levi & Korsinsky about pending Class ActionALT - ACCESS Newswire
Altimmune: Upcoming MASH Data Could Be High Impact For Business Development Activity (NASDAQ:ALT) - Seeking Alpha
Altimmune’s SWOT analysis: pemvidutide potential drives stock outlook By Investing.com - Investing.com India
Altimmune’s SWOT analysis: pemvidutide potential drives stock outlook - Investing.com
ALT Hosts Virtual Meeting to Discuss Strategic Developments | ALT Stock News - GuruFocus
Altimmune, Inc. (NASDAQ:ALT) Shares Acquired by Northern Trust Corp - Defense World
Could Altimmune, Inc. (ALT): Analysts See 288% Upside Potential - MSN
How Much Upside is Left in Altimmune (ALT)? Wall Street Analysts Think 285.86% - MSN
Will Pfizer Will Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback? - AOL.com
Altimmune (ALT) Stock Rises Amid Clinical Trial Progress: What's Going On? - Benzinga
Altimmune begins phase 2 trial for AUD treatment By Investing.com - Investing.com South Africa
Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluati - GuruFocus
Altimmune (ALT) Begins Phase 2 Trial for Pemvidutide in Treating Alcohol Use Disorder | ALT Stock News - GuruFocus
Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder - marketscreener.com
Altimmune begins phase 2 trial for AUD treatment - Investing.com
Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD) - The Manila Times
Breakthrough AUD Drug Enters Phase 2 Trial: New Hope for 28 Million US Patients With Alcohol Use Disorder - Stock Titan
HC Wainwright Has Strong Forecast for Altimmune Q2 Earnings - Defense World
William Blair Estimates Altimmune’s Q2 Earnings (NASDAQ:ALT) - Defense World
Price T Rowe Associates Inc. MD Acquires 4,158 Shares of Altimmune, Inc. (NASDAQ:ALT) - Defense World
B. Riley Issues Positive Estimate for Altimmune Earnings - Defense World
(ALT) Proactive Strategies - news.stocktradersdaily.com
Altimmune outlines phase 3 pemvidutide plans and expands to alcohol-related liver indications while extending cash runway - MSN
Baird Financial Group Inc. Takes Position in Altimmune, Inc. (NASDAQ:ALT) - The AM Reporter
Stifel Financial Corp Sells 4,649 Shares of Altimmune, Inc. (NASDAQ:ALT) - Defense World
Altimmune, Inc. (NASDAQ:ALT) Q1 2025 Earnings Call Transcript - Insider Monkey
Voya Investment Management LLC Decreases Stake in Altimmune, Inc. (NASDAQ:ALT) - Defense World
Altimmune Reports Better-Than-Feared Q1 Loss, Secures $100M Credit Facility: Retail’s Pleased - MSN
Piper Sandler maintains Altimmune stock with $25 target - Investing.com Australia
Piper Sandler maintains Altimmune stock with $25 target By Investing.com - Investing.com Nigeria
Altimmune to Participate at Two Upcoming Investor Conferences | - GuruFocus
Altimmune to Participate at Two Upcoming Investor Conferences | ALT Stock News - GuruFocus
Altimmune to Participate at Two Upcoming Investor Conferences - The Manila Times
Altimmune Sets Double Conference Appearance: HC Wainwright and Jefferies Healthcare Events Coming Up - Stock Titan
Altimmune’s 2025 Q1 Results Highlight Clinical Progress - TipRanks
Raymond James Financial Inc. Invests $88,000 in Altimmune, Inc. (NASDAQ:ALT) - Defense World
Altimmune Inc (ALT) Q1 2025 Earnings Call Highlights: Financial Strength and Strategic Developments - Yahoo Finance
Altimmune (ALT) Q1 Revenue Steady as Pemvidutide Developments Pr - GuruFocus
Earnings call transcript: Altimmune Q1 2025 results show narrower loss By Investing.com - Investing.com Canada
Altimmune, Inc. SEC 10-Q Report - TradingView
Altimmune (ALT) Advances NASH Treatment and Secures $100M Credit Facility - GuruFocus
Altimmune, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:ALT) - Seeking Alpha
ALTI Reports Strong Q1 Revenue Growth | ALTI Stock News - GuruFocus
Axsome’s $570M loan with Blackstone; Altimmune makes its own credit deal - Endpoints News
Earnings call transcript: Altimmune Q1 2025 results show narrower loss - Investing.com Australia
Altimmune (ALT) Sees Modest Pre-Market Rise After Earnings Report | ALT Stock News - GuruFocus
Altimmune, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Altimmune Secures Credit Facility of Up to $100 Million From Hercules Capital - marketscreener.com
Altimmune Q1 2025 Earnings Call Transcript - MarketBeat
Altimmune (ALT) Secures $100 Million Credit Facility to Advance Pemvidutide Development | ALT Stock News - GuruFocus
Altimmune secures $100 million credit facility for drug development - Investing.com
Altimmune Inc (ALT) 財務データ
収益
当期純利益
現金流量
EPS
1.89%
3.74%
大文字化:
|
ボリューム (24 時間):